Table 4
Parameter: RNA complexation | Reported procedure / limitation: N/P 10 selected; positivity plateaued near N/P 5, whereas fluorescence intensity was highest at N/P 10. | Source: Main Fig. 3 and optimization text
sales@dcchemicals.com
Lipid 6
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Table 4
Parameter: Phases / mixing | Reported procedure / limitation: Ethanol lipid phase and RNA in 10 mM citrate, pH 4; ethanol:aqueous 1:3 by microfluidic mixing. Total flow rate not located. | Source: STAR Methods
Table 4
Parameter: Purification | Reported procedure / limitation: 14 kDa dialysis against approximately 50 volumes DPBS overnight at 4 °C; 0.22 µm filtration. | Source: STAR Methods
Table 4
Parameter: T-cell preparation | Reported procedure / limitation: Activate for 48 h; IL-2 100 U/mL and 2% FBS in the reported culture workflow. LNP exposure 6 h, three washes, then expression readout. | Source: STAR Methods
Table 4
Parameter: Optimized T-cell condition | Reported procedure / limitation: 150 ng reporter mRNA per 5 × 10⁵ cells with ApoE4 1 µg/mL in the optimization text. | Source: Main Fig. 3; do not transfer this dose to the inconsistent CAR passage
Table 5
Measurement / batch: Initial-screen Lipid 6 LNP | Reported result: 79.6 nm; PDI 0.134; encapsulation 99.40%; zeta potential 1.13 mV | Evidence context: SI Table S1; not a B13-specific release specification
Table 5
Measurement / batch: Screened formulations | Reported result: 26 DOE entries, A1–A13 and B1–B13 | Evidence context: SI Table S2
Table 5
Measurement / batch: High-lipid-fraction formulations | Reported result: Some formulations containing 50% ionizable lipid precipitated on storage | Evidence context: Main optimization discussion
Table 6
Experiment and dose: Mouse reporter delivery Luciferase mRNA; intravenous or intramuscular; 0.5 mg/kg | Readout and comparator: Readout: 6 h; IM time-course also follows expression through 72 h Comparator: SM-102 and ALC-0315 study formulations | Result and source: Both routes were tested. The 6 h comparison and the IM persistence experiment are separate endpoints; no cross-route fold ratio is inferred. Fig. 2; n=3, mean ± SD; ANOVA as specified in the figure
Table 6
Experiment and dose: Formulation optimization Activated human T cells; eGFP reporter; optimization conditions above | Readout and comparator: Readout: 24 h expression assessment Comparator: Initial recipe and DOE formulations | Result and source: B11 and B13 yielded the strongest fluorescence intensity; B-series formulations produced >90% positive cells under the reported assay. Fig. 3; SI Table S2
Table 6
Experiment and dose: Cell-type breadth Reporter mRNA in primary immune-cell preparations | Readout and comparator: Readout: Study expression endpoint Comparator: Cell-type-specific untreated / assay controls | Result and source: Reported positivity: DC/NK >90%, TIL >97%, activated T cells >95%, unactivated T cells >80%. These are separate cell populations, not pooled efficacy. Fig. 4; n=3 donors
Table 6
Experiment and dose: CAR expression and phenotype Primary human T cells; CAR mRNA | Readout and comparator: Readout: 24 h CAR expression Comparator: Mock-treated cells | Result and source: Approximately 90% CAR-positive cells; viability, proliferation, CD4/CD8 distribution and tested exhaustion markers were not significantly altered in the reported comparison. CAR dose wording is inconsistent (see interpretation). Fig. 5; n=3
Table 6
Experiment and dose: Antigen-dependent killing MUC1-positive SKOV3 / MDA-MB-468 targets; 10⁴ target cells seeded 24 h before effectors; varied E:T ratios | Readout and comparator: Readout: Real-time cytotoxicity assay Comparator: Mock T cells and assay controls | Result and source: CAR T-cell activity depends on target line and E:T ratio. No single killing percentage is assigned across these conditions. Fig. 6; assay Methods
Table 6
Experiment and dose: Storage of RNA-loaded LNP 4 °C formulation storage; eGFP delivery assay | Readout and comparator: Readout: Up to 110 days Comparator: 25 °C and 37 °C storage conditions | Result and source: The SI reports near-complete eGFP positivity and >80% viability after 4 °C storage. Warmer conditions lose activity; this is not a neat-lipid shelf-life claim. SI Fig. S3